Arsinothricin and methods of treating infections using arsinothricin
View Patent ↗Certain embodiments of the invention pertain to a method of treating an infection in a subject caused by an infectious agent other than Escherichia coli , the method comprising administering to the subject arsinothricin or a salt thereof. The infectious agent other than E. coli can be a bacterium, protozoan, helminth, archaebacterium, or a fungus. In preferred embodiments, the infectious agent is Mycobacterium tuberculosis, Mycobacterium bovis , or Enterobacter cloacae . The invention also pertains to a method of treating an infection in a subject caused by an infectious agent, comprising administering to the subject arsinothricin or a salt thereof in combination with an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. In certain such embodiments, the infectious agent expresses phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. Further embodiments provide compositions comprising arsinothricin or a salt thereof and an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase.
1. A method of treating an infection in a subject caused by Enterobacter cloacae comprising administering to the subject arsinothricin or a salt thereof.
2. The method of claim 1 , wherein the infection is caused by carbapenem-resistant Enterobacter cloacae.
3. The method of claim 1 , wherein Enterobacter cloacae expresses phosphinothricin N-acetyltransferase and/or arsinothricin N-acetyltransferase, and the method further comprises administering to the subject an inhibitor of phosphinothricin N-acetyltransferase and arsinothricin N-acetyltransferase.
4. A method of treating an infection in a subject caused by a bacterium, the bacterium being Enterobacter spp. the method comprising administering to the subject arsinothricin or a salt thereof.
5. The method of claim 4 , comprising administering arsinothricin or salt thereof via oral, pulmonary, buccal, suppository, intravenous, intraperitoneal, intranasal, intramuscular, or subcutaneous route.
6. The method of claim 4 , wherein the bacterium is carbapenem-resistant Enterobacteriaceae, or carbapenem-resistant Enterobacter cloacae.
7. The method of claim 4 , wherein the bacterium does not express phosphinothricin N-acetyltransferase and/or arsinothricin N-acetyltransferase.
8. The method of claim 4 , wherein the bacterium expresses phosphinothricin N-acetyltransferase and/or arsinothricin N-acetyltransferase and the method further comprises administering to the subject an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase.
9. The method of claim 8 , wherein the inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase is:
2-({8-fluoro-5H-pyridazino[4,5-b]indol-4-yl}sulfanyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)acetamide;
3-oxo-N-({1-phenyl-1H,4H,5H, 6H-cyclopenta[c]pyrazol-3-yl}methyl)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide;
1-(4-fluorobenzoyl)-N-(3-phenyl-1H-pyrazol-4-yl)piperidine-3-carboxamide;
N-[3-({[(6-fluoro-3,4-dihydro-2H-1-benzopyran-4-yl)carbamoyl]amino}methyl)phenyl]cyclobutanecarboxamide; or
1-[1-(2-fluorobenzoyl)piperidin-4-yl]-3-[2-(3-fluorophenyl)cyclopropyl]urea.
10. The method of claim 4 , further comprising isolating the bacterium, testing the bacterium for the expression of phosphinothricin N-acetyltransferase and/or arsinothricin N-acetyltransferase, and administering to the subject an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase.
11. The method of claim 10 , wherein the inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase is:
2-({8-fluoro-5H-pyridazino[4,5-b]indol-4-yl}sulfanyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)acetamide;
3-oxo-N-({1-phenyl-1H,4H,5H, 6H-cyclopenta[c]pyrazol-3-yl}methyl)-3,4-dihydro-2H-1,4-benzothiazine-6-carboxamide;
1-(4-fluorobenzoyl)-N-(3-phenyl-1H-pyrazol-4-yl)piperidine-3-carboxamide;
N-[3-({[(6-fluoro-3,4-dihydro-2H-1-benzopyran-4-yl)carbamoyl]amino}methyl)phenyl]cyclobutanecarboxamide; or
1-[1-(2-fluorobenzoyl)piperidin-4-yl]-3-[2-(3-fluorophenyl)cyclopropyl]urea.
12. The method of claim 4 , wherein the bacterium is carbapenem-resistant Enterobacter cloacae.
13. The method of claim 1 , comprising administering arsinothricin or salt thereof via oral, pulmonary, buccal, suppository, intravenous, intraperitoneal, intranasal, intramuscular, or subcutaneous route.
14. The method of claim 1 , wherein Enterobacter cloacae does not express phosphinothricin N-acetyltransferase and/or arsinothricin N-acetyltransferase.